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A  critical  step  in  producing  the  annual  inactivated  inﬂuenza  vaccine  is  the  development  of high  yield (hy)
seed viruses  by reassortment  for improved  growth  in  ovo. Although  hy reassortants  for  type  A  inﬂuenza
viruses  have  been  developed  for many  years,  hy  B inﬂuenza  reassortant  virus  development  for  vaccine
production  has  proven  difﬁcult.  In this  study,  we have  developed  fourteen  hy inﬂuenza  type  B reassortants
as  vaccine  candidate  strains  with  B/Lee/40  as  the  donor  virus.  Upon  characterization  by  the  Inﬂuenza
Division  at the  Centers  for  Disease  Control  and  Prevention  (CDC)  and the  veriﬁcation  of HA  by  sequencing,
all  B reassortants  were  found  to  be antigenically  indistinguishable  from  the  wild  type  (wt)  parents  and
suitable  for  vaccine  production.  However,  only  one  hy  reassortant  seed  virus  from  this  group  was  used by  a
manufacturer  for vaccine  production.  In  general,  hy  reassortants  showed  an increase  in hemagglutination
(HA)  titers  over their  wt parents  by  approximately  8  fold  (range  1–32  fold).  Gene  compositions  of  the  hy  B
reassortants  were  analyzed  by restriction  fragment  length  polymorphism  (RFLP)  and  the  wt  origin  of  the
HA  and  neuraminidase  (NA) were  conﬁrmed.  However,  in  contrast  to hy A reassortants  which  require  the
M  gene  (hy donor  A/PR/8/34)  for high  yield,  all fourteen  hy  B reassortants  obtained  the  NP  gene  from  the  hy
donor  strain  (B/Lee/40).  The  parental  source  for  the remaining  genes  varied  among the  hy  B reassortants.
The  results  indicate  that  the  B/Lee/40  NP and  PB1  gene  segments  are  important  contributors  to high  yield
growth  in inﬂuenza  B reassortant  viruses  for both  Yamagata  and Victoria  lineages.  The  B/Lee/40  PB2  gene
along  with  wt  NS  gene  also contributed  to  the  improved  growth  for  hy  reassortants  of  Yamagata  lineage.
© 2014  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license. Introduction
A critical step in large-scale production of the inactivated
nﬂuenza virus vaccines is the development of high yield (hy) or
igh growth ‘seed’ viruses by classical reassortment. The hy seed
iruses have better growth properties than the corresponding wt
iruses. Using the reassortment method developed by Dr. E.D. Kil-
ourne in 1969 [1], inﬂuenza A hy reassortants have been routinely
repared to provide efﬁcient growth in embryonated chicken eggs
or vaccine production since 1971. However, it has been difﬁcult to
roduce hy reassortants for inﬂuenza type B viruses, even though
he reassortment of type B inﬂuenza may  occur with a frequency
qual to its type A counterpart [2].
∗ Corresponding author. Tel.: +1 914 594 4189; fax: +1 914 594 3770.
E-mail address: Doris Bucher@NYMC.EDU (D.J. Bucher).
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ttp://dx.doi.org/10.1016/j.vaccine.2014.12.027
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
As of 2012 the FDA has approved a quadrivalent vaccine com-
prised of two  type B viruses, one Yamagata and one Victoria
lineage in addition to the two  type A components. The additional
B component will increase the burden of the limited vaccine pro-
duction capacity. Therefore development and generation of high
yield inﬂuenza B reassortants for the seasonal inﬂuenza vaccine
may  become a critical component in facilitating the increased pro-
duction necessary for manufacture of the quadrivalent vaccine.
In the “classical” reassortment method, a hy donor strain is
co-infected in embryonated chicken eggs with the currently circu-
lating wild type (wt) strain to produce a hy virus that obtains one or
more ‘internal’ gene segments (up to six segments) from the donor
and the two genes for the surface antigenic proteins hemagglu-
tinin (HA) and neuraminidase (NA) from the wt  virus. The resultant
progeny viruses, which potentially have 28 or 256 different gene
segment combinations, are then subjected to antibody selection to
eliminate any viruses with HA and NA derived from the hy donor
virus. The viruses selected will have the targeted antigenicity of the
wt and the hy growth characteristics of the donor strain. However,
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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to amplify the cDNAs using a Takara One Step RNA PCR kit (Takara
Bio Inc., Otsu, Shiga, Japan). RFLP was performed using two different
restriction endonucleases for each viral gene segment (Table 1).
Table 180 J. Le et al. / Vacci
 similar approach was tried with type B inﬂuenza virus with little
r no success [3,4]. The efforts in creating hy inﬂuenza B reassor-
ants suitable for vaccine production encountered difﬁculties either
n selecting the appropriate NA gene [5,6] or in maintaining the hy
roperty [4]. Although Podchernyaeva et al. [7] reported success
n generating hy B reassortants, the origin of the internal six gene
egments was not determined.
Reverse genetics (rg) based on rescuing infectious viruses from
ransfected plasmids that encode the eight gene segments of
nﬂuenza has been used in developing reassortant viruses. In rg
he genes encoding the two surface proteins (HA and NA) from
he wt virus and the six internal gene segments from the hy
onor virus are cloned into eight plasmids and then transfected
nto cells. Using an eight-plasmid system, reverse genetics has
een successfully applied to creating inﬂuenza B reassortants
8].
Though reverse genetics is an invaluable tool in studying the
iology of inﬂuenza viruses, it is worth noting that classical reas-
ortment offers advantages in hy seed virus development for
nﬂuenza vaccine production. Classical reassortment is performed
ntirely in embryonated chicken eggs, allowing the selection of
ene combinations and viral variants (or minor mutations) that
aximize the viral growth potential in the substrate. In compar-
ng the two methods in the development of the 2009 pandemic
nﬂuenza seed virus, Robertson et al. [9] reported that both meth-
ds were capable of generating reassortants with a preparation
ime between 18 and 23 days. However, hy reassortants NYMC
-179A and X-181 produced by classical reassortment produced
igher yields in ovo and were the hy seed viruses of choice by
he majority of the vaccine manufacturers. The 5:3 gene conﬁgura-
ion (ﬁve internal genes from hy donor and three gene segments:
A, NA and PB1 from wt A/California/07/2009) together with
mino acid changes in the HA of the X-179A and X-181 [9] con-
ributed to their high yield properties without altering antigenicity.
he 5:3 gene conﬁguration and the HA amino acid changes are
hought to be the results of positive selection by the host system
eggs).
In this study we produced fourteen genetically stable (no
equence changes detected after three passages) hy reassortants
or inﬂuenza B viruses using classical reassortment. These hy seed
iruses demonstrated an increased HA titer by approximately eight
old on average and were veriﬁed by the Inﬂuenza Division at
he CDC to be antigenically indistinguishable from their wt par-
nts. By analyzing the gene composition of these reassortants,
e found that in contrast to hy A reassortants that require the
 gene from the hy donor [10,11], all fourteen hy B reassor-
ants obtained the NP gene from the hy donor strain. The parental
ource for the remaining genes varied among the hy B reassor-
ants. The results indicate that the B/Lee/40 NP gene contributes
o high yield growth in inﬂuenza type B reassortant viruses. From
he analysis, we  also found that NP and PB1 from B/Lee/40 were
mportant contributors for Victoria lineage reassortants while NP,
B1 and PB2 genes from hy donor B/Lee/40 along with the NS
ene from wt viruses were important contributing factors of the
igh growth properties for Yamagata lineage inﬂuenza reassor-
ants.
. Methods
.1. VirusesAll viruses were provided by CDC. Six wt viruses were of the
amagata lineage while the remaining 4 were of the Victoria lin-
age. From these ten wt viruses, fourteen hy reassortant viruses
ere developed (Table 2).(2015) 879–884
2.2. Preparation of selective antisera and antibodies for
reassortment
The antiserum and antibodies for negative selection against
the hy donor strain (B/Lee/40) used in the development of the
hy reassortants were obtained by immunizing rabbits with solu-
bilized B/Lee/40 surface glycoprotein HA and NA using a procedure
described by Gallagher et al. [12]. The antisera were then adsorbed
with the target wt virus to reduce cross reactivity with wt inﬂuenza
B viruses. Antibodies were also chromatographically puriﬁed from
antisera by using Protein G columns. To further enrich the NA a
procedure developed by Bucher [13] was  implemented to produce
anti-NA antisera against B/Lee/40 in order to enhance the selection
against donor neuraminidase.
2.3. Production of reassortant viruses
A mixture of 50 l of diluted 1:104 of hy donor virus (B/Lee/40)
in PBS with 0.025% gentamicin and 50 l of diluted wild type virus
(dilution factors vary depending on initial viral titer) was inoc-
ulated into 11-day-old speciﬁc pathogen free (SPF) embryonated
chicken eggs (Charles River Laboratories, North Franklin, CT). The
eggs were incubated for 62–66 h at 33 ◦C, and chilled overnight
at 4 ◦C. The resultant reassorted progeny viruses underwent three
sequential passages for negative selection in eggs with antibod-
ies to B/Lee/40 hemagglutinin and neuraminidase together with
extra antisera to puriﬁed B/Lee/40 NA to exclude any viruses with
B/Lee/40 HA and NA genes. Three additional passages (includ-
ing two cloning passages) were performed without addition of
antibodies to provide positive selection (that is the higher grow-
ing reassortants would outcompete the lower growing reassortant
viruses). Candidate reassortants with the highest titers and wt HA
and NA were selected. The parental origin of all eight gene segments
was determined by RT-PCR/RFLP. The selected hy reassortants were
then cloned by limiting dilution and expanded to form a seed virus
pool.
2.4. Hemagglutination assay
Hemagglutination assays (HA) were performed by a method
modiﬁed from Hierholzer et al. [14] and the WHO  manual [15].
HA titer of the ﬁnal hy reassortant seed virus was compared with
the HA titer of the original wt  virus, and the yield fold increase was
then expressed as the HA titer ratio between the reassortant and
its wt  counterpart.
2.5. Identiﬁcation of parental origin of gene segments in
reassortant viruses via RT-PCR/RFLP
All eight-gene segments of inﬂuenza reassortants were identi-
ﬁed by the use of reverse transcriptase polymerase chain reaction
(RT-PCR) and restriction fragment length polymorphism (RFLP)
analysis [6,11,16–19]. The segment-speciﬁc primers [20] are usedRestriction enzymes for RFLP analysis of inﬂuenza type B viruses.
PB1 PB2 PA HA NP NA M NS
Enzyme I Bsg I Ban II Bae I Xmn  I Hind III Pvu II Kpn I Ban I
Enzyme II Eco57I Bsa I Sml  I Pvu II Eae I Bsa I Bsa I Mme  I
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Table  2
Gene composition of HY B reassortants.
Reassortants WT Viruses PB1 PB2 PA HA NP NA M NS Gene Ratio Lee/WT Lineage
BX-5A B/Jilin/20/2003 Lee Lee Lee WT  Lee WT Lee WT 5/3 Yamagata
BX-7  B/Jiangsu/10/2003 WT  WT WT WT  Lee WT Lee WT 2/6
BX-11 B/Florida/7/2004 Lee Lee WT WT  Lee WT WT WT 3/5
BX-21 B/Florida/04/2006 Lee Lee WT WT  Lee WT Lee WT 4/4
BX-21A B/Florida/04/2006 Lee Lee Lee WT  Lee WT Lee WT 5/3
BX-23 B/Pennsylvania/07/2007 Lee Lee Lee WT  Lee WT Lee WT 5/3
BX-23A B/Pennsylvania/07/2007 Lee Lee WT WT  Lee WT WT WT 3/5
BX-25 B/Bangladesh/3333/2007 Lee Lee WT WT  Lee WT WT WT 3/5
BX-25A B/Bangladesh/3333/2007 Lee Lee WT WT  Lee WT WT WT 3/5
Donor gene frequency 8/9* 8/9* 3/9 NA 9/9* NA 5/9 0/9*
BX-3 B/Hong Kong/1434/2002 Lee Lee Lee WT  Lee WT Lee WT 5/3 Victoria
BX-15 B/Hawaii/33/2004 Lee WT Lee WT  Lee WT WT Lee 4/4
BX-15A B/Hawaii/33/2004 Lee WT Lee WT  Lee WT Lee Lee 5/3
BX-17 B/Malaysia/2506/2004 Lee Lee WT WT  Lee WT WT WT 3/5
BX-19 B/Ohio/01/2005 Lee WT WT WT  Lee WT WT WT 2/6
Donor gene frequency 5/5* 2/5 3/5 NA 5/5* NA 2/5 2/5
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wee: hy donor virus B/Lee/40 gene segment; WT:  wild type virus gene segment.
* Statistically signiﬁcant at p < 0.05.
.6. Statistical analysis
Pearson Chi-square test was used to infer the statistical signiﬁ-
ance of the gene origin frequency based on the assumption that the
eassortant viruses would inherit a particular donor internal gene
egment at a frequency of 50% if the process was  purely random.
tudent’s t-test was used to compare the HA yield among reassor-
ant groups with the same number of B/Lee/40 internal genes. A
alue of p < 0.05 was considered statistically signiﬁcant.
. Results
.1. Development of the high yield inﬂuenza B reassortants
A series of hy inﬂuenza B reassortants for both Yamagata lin-
age and Victoria lineage wt viruses were generated (Table 2). In
otal, nine hy reassortant inﬂuenza B viruses were created from 6
amagata lineage wt viruses, Five hy reassortants were created for
 Victoria linage wt viruses.
.2. Gene analysis
cDNA was produced using primers derived from gene segment
peciﬁc sequences of the non-coding regions depicted by Stoeckle
t al. [20]. RFLP analysis was performed to determine the origin of
ach gene segment (Table 2). For example, hy reassortant NYMC BX-
 was determined by RFLP (Fig. 1) to have a 5:3 gene conﬁguration
ith 5 internal gene segments derived from hy donor B/Lee/40,
nd two surface gene segments (HA and NA) and one internal gene
egment (NS) from wt  virus B/Hong Kong/1434/2002. The origin of
he eight gene segments for all 14 hy reassortants is summarized
n Table 2.
All the hy reassortants obtained the HA and NA genes from
heir corresponding wt viruses (Table 2). When compared to type
 hy reassortants, which generally required the M gene from hy
onor (A/PR/8/34) for efﬁcient growth in eggs [10,11], only ﬁve of
ine Yamagata lineage reassortants and two of ﬁve Victoria lineage
eassortants obtained their M gene from the hy donor B/Lee/40.
owever, all hy type B reassortants of both Yamagata and Victo-
ia lineage obtained the NP gene from the hy donor. The origin of
he other gene segments varied among reassortants. In the Yama-
ata lineage, eight out of nine reassortants obtained their PB1 and
B2 genes from B/Lee/40, only BX-7 had both PB1 and PB2 from
t. In the Victoria lineage all the reassortants obtained their PB1from the B/Lee/40 donor, while only two  (BX-3 and BX-17) of the
ﬁve reassortants derived their PB2 from the B/Lee/40 donor. The
remaining three reassortants (BX-15, BX-15A and BX-19) derived
their PB2 from the respective wt  parent. Three out of nine Yamagata
lineage reassortants and three out of ﬁve Victoria lineage reassor-
tants obtained their PA gene from B/Lee/40. All nine reassortants in
the Yamagata lineage obtained the NS gene from wt while three of
the ﬁve Victoria lineage reassortants acquired NS from the wt. For
the Yamagata lineage reassortants the frequency of deriving the
PB1, PB2, NP and NS gene segments from the B/Lee/40 hy donor
was 8/9, 8/9, 9/9 and 0/9 respectively. The frequencies of these
gene segments are statistically signiﬁcant based on an expected
50% occurrence if the selection of the internal gene segments was a
random process (Table 2). In the Victoria lineage reassortants, only
the frequency of deriving PB1 (5/5) and NP (5/5) gene segments
from the B/Lee/40 hy donor are statistically signiﬁcant. The gene
ratio (number of donor genes to that of wt  genes) of hy inﬂuenza B
reassortants analyzed in this study varied from 2:6 to 5:3 (Table 2).
Three Yamagata lineage reassortants (BX-5A, BX-21A and BX-23)
and two Victoria lineage reassortants (BX-3 and BX-15A) had a 5:3
gene conﬁguration. One of each Yamagata and Victoria lineage reas-
sortants (BX-21 and BX-15, respectively) had a 4:4 gene ratio. Four
Yamagata lineage reassortants (BX-11, BX-23A, BX-25, and BX-25A)
and one Victoria lineage reassortant (BX-17) had a 3:5 gene ratio.
The aforementioned ﬁve reassortants with the 3:5 gene ratio all
had the same gene constellation pattern, deriving the PB1, PB2 and
NP from the hy donor. Lastly, one of each Yamagata and Victo-
ria lineage reassortants (BX-7 and BX-19, respectively) had a 2:6
gene ratio. Although the most frequent gene ratios in this panel of
hy B reassortants were 5:3 (∼36%) and 3:5 (∼36%), there was  no
clear pattern associating any speciﬁc gene ratio with HA lineage or
with hy phenotype. Nevertheless, it is worth noting that in addi-
tion to all the Yamagata lineage reassortants deriving their NP gene
from B/Lee/40, all the Yamagata lineage reassortants also obtained
their NS gene from wt virus and all but one (BX-7) Yamagata lin-
eage reassortants obtained both PB1 and PB2 from the hy donor.
All the Victoria lineage reassortants acquired PB1 and NP from
B/Lee/40, while three of ﬁve Victoria lineage reassortants had NS
from wt.3.3. Yield assessment
The fold increase of the HA titer was  expressed as the ratio
of HA titer between hy reassortant and the wt virus (Fig. 2).
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Fig. 1. Restriction fragment length polymorphism analysis of NYMC BX-3. NYMC BX-3 generated from B/Hong Kong/1434/2002 × B/Lee/40 has a 5:3 gene ratio. The HA, NA
and  NS gene segments were derived from wt  virus, with the remaining internal genes derived from B/Lee/40. (A) PB1: lane 1: B/Lee/40 undigested; 2: B/Lee/40 digested with
Bsg  I; 3: B/Lee/40 digested with Eco57I; 4: B/Hong Kong/1434/2002 undigested; 5: B/Hong Kong/1434/2002 digested with Bsg I; 6: B/Hong Kong/1434/2002 digested with
Eco57I; 7: NYMC BX-3 undigested; 8: NYMC BX-3 digested with Bsg I; 9: NYMC BX-3 digested with Eco57I. (B) PB2: lane 1: B/Lee/40 undigested; 2: B/Lee/40 digested with
Ban  II; 3: B/Lee/40 digested with Bsa I; 4: B/Hong Kong/1434/2002 undigested; 5: B/Hong Kong/1434/2002 digested with Ban II; 6: B/Hong Kong/1434/2002 digested with
Bsa  I; 7: NYMC BX-3 undigested; 8: NYMC BX-3 digested with Ban II; 9: NYMC BX-3 digested with Bsa I. (C) PA: lane 1: B/Lee/40 undigested; 2: B/Lee/40 digested with Bae
I;  3: B/Lee/40 digested with Sml  I; 4: B/Hong Kong/1434/2002 undigested; 5: B/Hong Kong/1434/2002 digested with Bae I; 6: B/Hong Kong/1434/2002 digested with Sml
I;  7: NYMC BX-3 undigested; 8: NYMC BX-3 digested with Bae I; 9: NYMC BX-3 digested with Sml  I. (D) HA: lane 1: B/Lee/40 undigested; 2: B/Lee/40 digested with Xmn  I;
3:  B/Lee/40 digested with Pvu II; 4: B/Hong Kong/1434/2002 undigested; 5: B/Hong Kong/1434/2002 digested with Xmn  I; 6: B/Hong Kong/1434/2002 digested with Pvu II;
7:  NYMC BX-3 undigested; 8: NYMC BX-3 digested with Xmn I; 9: NYMC BX-3 digested with Pvu II. (E) NP: lane 1: B/Lee/40 undigested; 2: B/Lee/40 digested with Hind III;
3:  B/Lee/40 digested with Eae I; 4: B/Hong Kong/1434/2002 undigested; 5: B/Hong Kong/1434/2002 digested with Hind III; 6: B/Hong Kong/1434/2002 digested with Eae
I;  7: NYMC BX-3 undigested; 8: NYMC BX-3 digested with Hind III; 9: NYMC BX-3 digested with Eae I. (F) NA: lane 1: B/Lee/40 undigested; 2: B/Lee/40 digested with Pvu
II;  3: B/Lee/40 digested with Bsa I; 4: B/Hong Kong/1434/2002 undigested; 5: B/Hong Kong/1434/2002 digested with Pvu II; 6: B/Hong Kong/1434/2002 digested with Bsa
I;  7: NYMC BX-3 undigested; 8: NYMC BX-3 digested with Pvu II; 9: NYMC BX-3 digested with Bsa I. (G) M: lane 1: B/Lee/40 undigested; 2: B/Lee/40 digested with Kpn I;
3:  B/Lee/40 digested with Bsa I; 4: B/Hong Kong/1434/2002 undigested; 5: B/Hong Kong/1434/2002 digested with Kpn I; 6: B/Hong Kong/1434/2002 digested with Bsa I;
7:  NYMC BX-3 undigested; 8: NYMC BX-3 digested with Kpn I; 9: NYMC BX-3 digested with Bsa I. (H) NS: lane 1: B/Lee/40 undigested; 2: B/Lee/40 digested with Ban I; 3:
B/Lee/40 digested with Mme  I; 4: B/Hong Kong/1434/2002 undigested; 5: B/Hong Kong/1434/2002 digested with Ban I; 6: B/Hong Kong/1434/2002 digested with Mme  I; 7:
NYMC  BX-3 undigested; 8: NYMC BX-3 digested with Ban I; 9: NYMC BX-3 digested with Mme  I.
J. Le et al. / Vaccine 33 
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Fig. 2. Comparison of the HA titer between HY reassortants and their corresponding
WT  viruses. The yield fold increase indicated at the top of the bar graphs is expressed
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reassortants obtained the NS gene from B/Lee/40. The wt par-
ent NS gene segment is preferably selected by Yamagata lineage
viruses (9/9) in contrast to Victoria lineage viruses (3/5, Table 2)
during the reassortment process. The NS1 protein, one of the twos  the ratio between the HA titer of the hy reassortants and their respective wt
iruses. (A) Yamagata lineage; (B) Victoria lineage. *: no increase in yield between
eassortant and wt  ( wt,   hyr).
ll nine hy reassortants generated from Yamagata lineage wt
iruses had fold increases in their HA titers ranging from 3 to
2. Reassortant BX-7 along with BX-11 and BX-23 had threefold
ncreases; BX-23A had a ﬁvefold increase; BX-21A and BX-25A
ad eightfold increases; BX-25, BX-5A and BX-21 had 16, 21
nd 32 fold increases, respectively. Three of the ﬁve Victoria
ineage hy reassortants had a 2 fold increase (BX-17), 3 fold
ncrease (BX-15) and 16 fold increase (BX-3) in HA titer, while the
emaining two reassortants (BX-15A and BX-19) had no increase in
A titer.
The average fold increase in HA titer for the Yamagata lineage
y reassortants was 12.1, which was higher than that for the Vic-
oria lineage hy reassortants (4.6). The reassortants with more hy
/Lee/40 internal genes had higher fold increases in HA titer when
ll the reassortants were grouped according to the same number of
/Lee/40 internal genes regardless of the lineage (Fig. 3). The aver-
ge HA titers for reassortants with two, three, four or ﬁve B/Lee/40
nternal genes regardless of the lineage were 2, 6.8, 17.0 and 9.8,
espectively. However, such differences were not statistically sig-
iﬁcant.
. Discussion
Inﬂuenza A hy reassortant seed viruses have been routinely
eveloped for enhancing virus growth for vaccine production
or more than 40 years. However, attempts to develop hy
nﬂuenza B reassortants were largely unsuccessful, partially due
o the lack of an A/PR/8/34 equivalent hy inﬂuenza B donor
4].
A suitable hy donor virus should have the following properties:
1) safe to use in human vaccines; (2) high growth in eggs; (3) anti-
enically distinct from the current vaccine strain to allow effective
election by antibodies or antisera. Under these criteria, B/Lee/40
s a good choice for use as a hy donor for developing hy B reas-
ortants. First, B/Lee/40 was safely used as the B component of the(2015) 879–884 883
trivalent vaccine in 1947 [21]. Second, B/Lee/40 has been passed in
eggs for many years, acquiring the high yield phenotype. Also com-
paring B/Lee/40 with ten other possible hy donors, we found that
B/Lee/40 had 3.5–20 times higher yield as measured by the amount
of viral protein per egg [22].
We found that the antisera raised against the HA and NA
of B/Lee/40 was  effective in eliminating the HA of B/Lee/40.
However, the antisera had shown cross reactivity between the
neuraminidases of B/Lee/40 and the wt viruses. In this study,
we were able to overcome some of the difﬁculties with cross
reactivity by absorbing the B/Lee/40 HA and NA antisera with
wt target viruses. Furthermore, we  used puriﬁed B/Lee/40 NA to
immunize rabbits to produce antisera that was more selective
against B/Lee/40 NA to address the difﬁculties encountered by
Beare et al. and Vodeiko et al. [5,6] in selecting B reassortants with
wt NA.
In order to identify a correlation between the gene constella-
tion and the hy phenotype of the reassortants we  analyzed the
parental origins of the gene segments in all the reassortants. In
contrast to hy type A reassortants which acquired the M gene
from the donor A/PR/8/34, 50% of the inﬂuenza B reassortants
(ﬁve of nine Yamagata lineage reassortants and two  of ﬁve Vic-
toria lineage reassortants) obtained their M gene from the hy
donor B/Lee/40 (Table 2). This may  indicate that the M gene
from the hy donor in inﬂuenza B reassortants is not as criti-
cal as that in inﬂuenza A for the hy phenotype. In this study,
the NP gene from B/Lee/40 was found in all hy reassortants
regardless of the lineage. In addition, both the PB1 and PB2 gene
segments of B/Lee/40 were found in all but one (BX-7) Yama-
gata lineage reassortants. All Victoria lineage reassortants acquired
PB1 from B/Lee/40, while two reassortants (BX-3 and BX-17)
obtained PB2 from the hy donor. This suggests that the PB1, PB2
and NP genes for the B/Lee/40 polymerase complex contributed
to the hy phenotype of the Yamagata lineage hy reassortants,
while the combination of PB1 and NP of B/Lee/40 are sufﬁcient in
the Victoria lineage hy reassortants. Interestingly, PA of B/Lee/40
was not favored by either lineage in their respective hy reassor-
tants.
The Yamagata lineage reassortants acquired the NS from wt
virus, as did three out of ﬁve Victoria lineage reassortants. This
is in contrast to the study by Goodeve et al. [4], in which all theFig. 3. Average HA yield fold increase among reassortants grouped by number of
donor B/Lee/40 internal genes.
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roteins encoded by NS gene segment is recognized as an
nterferon antagonist for both inﬂuenza A [23] and B viruses
24]. It is possible that the interferon antagonist activity
f the NS1 protein from wt is more critical for Yamagata
ineage reassortant viruses than Victoria lineage reassortant
iruses.
We found that HA titers of the hy inﬂuenza B reassortants with
ore internal donor B/Lee/40 genes were generally higher than
hose reassortants with fewer genes. This was also observed in
he hy inﬂuenza A viruses [11]. However, such positive correla-
ions between the number of B/Lee/40 internal genes and HA titers
ere not statistically signiﬁcant, possibly due to the small sample
ize. To understand such correlations further, complete sequences
f all the gene segments from those reassortant viruses and their
orresponding wt viruses may  reveal more about the effect of the
hanges at the nucleotide levels on the viral growth (HA titer) in
mbryonated chicken eggs.
In the process of generating these fourteen reassortants we did
ot obtain any reassortants with a 6:2 gene conﬁguration. Con-
ersely in the analysis of 57 hy inﬂuenza A reassortants generated
n our laboratory for seed virus to produce the inactivated inﬂuenza
 vaccine component, 56% of the reassortants generated had a 6:2
ene conﬁguration [11]. For the inﬂuenza B, there was  no such
ene conﬁguration yielding a hy phenotype to the majority of the
eassortants generated.
Our experience has shown that B/Lee/40 is not the type B
ounterpart of the type A donor A/PR/8/34. Type A reassortants
mplementing A/PR/8/34 as a hy donor have consistently pro-
uced hy seed virus. In a study of 57 hy A reassortants employing
/PR/8/34 as the hy donor, 88% of the resultant reassortants had
8-fold increases in HA titer over the wt parent virus [11]. In
his analysis of hy B reassortants produced using B/Lee/40 as
he hy donor 43% attained a ≥8-fold increase in HA titer over
t, while two reassortants, BX-15A and BX-19 had no change
n HA titer compared to their wt parents (Fig. 2). Even though
/Lee/40 itself can produce high growth [22], there is a possi-
ility that such a property is at least partially achieved through
utations in the HA from countless passages in eggs. Therefore, it
s advisable to continue the search for other potential hy donors
or inﬂuenza B reassortment. Nevertheless, we were able to over-
ome some of the limitations of utilizing the hy donor B/Lee/40
nd develop a series of hy B reassortants for vaccine produc-
ion.
To the best of our knowledge, these were the ﬁrst hy B reassor-
ants suitable for inactivated inﬂuenza vaccine production in eggs.
X-17, the hy reassortant for B/Malaysia/2506/2004 was submit-
ed for evaluation for potential use in vaccine production during
he 2006–2007 inﬂuenza season, and was reported to have been
sed in the vaccine by at least one manufacturer (personal com-
unication).
The gene analysis showed that gene composition for hy B reas-
ortants can vary from 2:6 to 5:3. The NP, PB1 and PB2 of the
/Lee/40 polymerase complex are important to the hy property of
he Yamagata lineage reassortants, while the NP and PB1 of the
/Lee/40 are important for the Victoria lineage reassortants. Addi-
ionally the wt NS gene is favored in the hy phenotype of Yamagata
ineage reassortants.
Future research and development of hy inﬂuenza B reassortants
s essential to produce an annual quadrivalent vaccine in sufﬁcient
oses for the population. A better understanding of the hy genotype
an aid vaccine production and also basic research in producing
y phenotype inﬂuenza B viruses. This work details the feasibility
f generating hy inﬂuenza B seed viruses and further contributes
o our understanding of the genes necessary for the hy genotype
n inﬂuenza B hy seed viruses produced from classical reassort-
ent.
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